Looking beyond Roche’s Tigit bombshell
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
What now for low-cost PD-(L)1 competition?
The prospects for Chinese competitors, ongoing controversy in cervical cancer and a super-fast approval take centre stage.
Go or no go? Bristol’s Lag3 debut
March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
How China applicants could avoid the sintilimab scenario
A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.
